IL291667A - Biomarker panel targeted to diseases due to multifactorial ontology of glycocalyx disruption - Google Patents
Biomarker panel targeted to diseases due to multifactorial ontology of glycocalyx disruptionInfo
- Publication number
- IL291667A IL291667A IL291667A IL29166722A IL291667A IL 291667 A IL291667 A IL 291667A IL 291667 A IL291667 A IL 291667A IL 29166722 A IL29166722 A IL 29166722A IL 291667 A IL291667 A IL 291667A
- Authority
- IL
- Israel
- Prior art keywords
- multicausal
- glycocalyx
- ontology
- disorder
- disease
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/328—Vasculitis, i.e. inflammation of blood vessels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962907389P | 2019-09-27 | 2019-09-27 | |
| PCT/US2020/052912 WO2021062298A1 (en) | 2019-09-27 | 2020-09-25 | Biomarker panel targeted to diseases due to multifactorial ontology of glycocalyx disruption |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL291667A true IL291667A (en) | 2022-05-01 |
Family
ID=75166872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL291667A IL291667A (en) | 2019-09-27 | 2022-03-24 | Biomarker panel targeted to diseases due to multifactorial ontology of glycocalyx disruption |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220390454A1 (https=) |
| EP (1) | EP4034164A4 (https=) |
| JP (1) | JP7689518B2 (https=) |
| AU (1) | AU2020356626A1 (https=) |
| CA (1) | CA3155843A1 (https=) |
| IL (1) | IL291667A (https=) |
| WO (1) | WO2021062298A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016123163A2 (en) | 2015-01-27 | 2016-08-04 | Kardiatonos, Inc. | Biomarkers of vascular disease |
| US12105099B2 (en) | 2021-04-28 | 2024-10-01 | Diotex Diagnostics, Llc | Methods and devices for quantitatively estimating syndecan-1 |
| CN115389773A (zh) * | 2022-09-22 | 2022-11-25 | 无锡市第二人民医院 | 糖萼脱落标志物在诊断和防治初发的2型糖尿病肾病早期肾损伤的应用 |
| WO2025049608A1 (en) * | 2023-08-28 | 2025-03-06 | Calroyhealth Sciences, Llc | Compositions and methods to protect and enhance structural and functional integrity of the intestinal glycocalyx |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2437491T3 (es) * | 2003-10-10 | 2014-01-10 | Alchemia Oncology Pty Limited | Modulación de la síntesis y degradación de hialuronano en el tratamiento de enfermedad |
| CA2511269A1 (en) * | 2004-07-07 | 2006-01-07 | F. Hoffmann-La Roche Ag | Multimarker panel based on p1gf for diabetes type 1 and 2 |
| EP2302395B1 (en) * | 2006-06-07 | 2015-04-15 | Health Diagnostic Laboratory, Inc. | Markers associated with arteriovascular events and methods of use thereof |
| WO2008080030A2 (en) * | 2006-12-22 | 2008-07-03 | Abbott Laboratories | Cardiovascular autoimmune disease panel and methods of using same |
| WO2011115783A1 (en) * | 2010-03-15 | 2011-09-22 | Oregon Health & Science University | Methods for assessing the risk of cardiovascular disease |
| WO2012106152A1 (en) * | 2011-02-03 | 2012-08-09 | Abbott Laboratories | Methods of prognosis and diagnosis in chronic heart failure |
| US9086412B2 (en) * | 2012-12-31 | 2015-07-21 | University Of Louisville Research Foundation, Inc. | Extracellular vesicle-associated protein markers of cancer |
| EP2965088B1 (en) * | 2013-03-04 | 2018-12-05 | IQ Products B.V. | Prognostic marker to determine the risk for early-onset preeclampsia |
| WO2016123163A2 (en) * | 2015-01-27 | 2016-08-04 | Kardiatonos, Inc. | Biomarkers of vascular disease |
| WO2016126662A1 (en) * | 2015-02-03 | 2016-08-11 | Kardiatonos, Inc. | Compounds for the prevention and treatment of vascular disease |
| WO2016164534A1 (en) * | 2015-04-09 | 2016-10-13 | Kardiatonos, Inc. | Methods and compositions for reversing disruption of the glycocalyx, inflammation, and oxidative damage |
| WO2016176089A1 (en) * | 2015-04-29 | 2016-11-03 | Kardiatonos, Inc. | Methods and compositions for reversing disruption of the glycocalyx, inflammation, and oxidative damage |
| WO2017136652A1 (en) * | 2016-02-04 | 2017-08-10 | Tarveda Therapeutics, Inc. | Stapled peptide conjugates and particles |
| JP7420557B2 (ja) * | 2017-03-07 | 2024-01-23 | オルト-クリニカル ダイアグノスティックス インコーポレイテッド | 分析物を検出するための方法 |
-
2020
- 2020-09-25 CA CA3155843A patent/CA3155843A1/en active Pending
- 2020-09-25 JP JP2022519782A patent/JP7689518B2/ja active Active
- 2020-09-25 EP EP20868963.8A patent/EP4034164A4/en active Pending
- 2020-09-25 US US17/762,703 patent/US20220390454A1/en active Pending
- 2020-09-25 WO PCT/US2020/052912 patent/WO2021062298A1/en not_active Ceased
- 2020-09-25 AU AU2020356626A patent/AU2020356626A1/en not_active Abandoned
-
2022
- 2022-03-24 IL IL291667A patent/IL291667A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021062298A1 (en) | 2021-04-01 |
| JP2022549373A (ja) | 2022-11-24 |
| EP4034164A1 (en) | 2022-08-03 |
| CA3155843A1 (en) | 2021-04-01 |
| JP7689518B2 (ja) | 2025-06-06 |
| EP4034164A4 (en) | 2024-01-24 |
| AU2020356626A1 (en) | 2022-04-14 |
| US20220390454A1 (en) | 2022-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL291667A (en) | Biomarker panel targeted to diseases due to multifactorial ontology of glycocalyx disruption | |
| HUE058002T2 (hu) | Többportos egységek rögzítõelemekkel | |
| EP3676792A4 (en) | DYNAMIC SCRIPTS FOR TELEAGENTS | |
| MA51561A (fr) | Panneau | |
| IL253756A0 (en) | Biomarker panel for the detection of cancer | |
| EP3365371C0 (en) | GITR AGONISTS | |
| EP2972393A4 (en) | BIOMARKERS AND METHOD FOR PREDICTING PREECLAMPSIA | |
| BR112017022117A2 (pt) | “sondas duplas supressoras” | |
| ITUB20152915A1 (it) | Dispositivo a cerniera con lunga traslazione di un pannello frontale | |
| EP3003038A4 (en) | SMALL MOLECULAR FIBROSIS HEMMER | |
| IL256762A (en) | Fgfr expression and susceptibility to an fgfr inhibitor | |
| EP2983591A4 (en) | PREDICTIVE AND RESPONSE BIOMARKERS FOR TH-302 CANCER THERAPY | |
| EP2951379A4 (en) | ARRANGEMENT OF ELECTRIC OPTICAL WINDOW | |
| HRP20182052T1 (hr) | Prognoza biomarkera kod poremećaja hrskavice | |
| MA43958A (fr) | Biomarqueurs copanlisib | |
| EP3637172A4 (en) | OPTICAL STRUCTURE | |
| EP3779083A4 (en) | GLASS PANEL SUPPORT STRUCTURE | |
| EP3394291A4 (en) | TRIAGE BIOMARKERS AND USES THEREOF | |
| EP2812698A4 (en) | BY DOUBLE ACCEPTOR TIME RELEASED FRET | |
| EP3520115A4 (en) | RESEARCH IMPLEMENTED BY COMPUTER OF BIOMARKERS OF THE INTERRUPTION OF THE HEMATOENCEPHALIC BARRIER | |
| IT201700037854A1 (it) | Pannello trasparente | |
| MA44484A (fr) | Biomarqueurs de protéinopathies et utilisations associées | |
| HUE060884T2 (hu) | Homogén immunesszé háttérjel kompenzációjára | |
| EP4127355C0 (en) | SIGN | |
| HUE058786T2 (hu) | FGF-18 vegyületre vonatkozó válaszkészség elõrejelzésére szolgáló metabolikus biomarkerek |